Abstract Library

#3462 Development and verification of a new monoclonal OTP specific antibody for pulmonary carcinoid diagnostics

Introduction: Histology-based grading of pulmonary carcinoids (PC) is problematic and subject to high interobserver variation. Orthopedia homeobox (OTP) has shown to be an excellent prognostic marker for PCs, also indicated by the WHO. However, absence of a reliable routinely applicable monoclonal OTP antibody (mAb) hampers implementation in routine diagnostics.

Conference:

Presenting Author: Speel E

Authors: Moonen L, Derks J, Lap L, Marijnissen B, van den Bosch T,

Keywords: Orthopedia Homeobox, pulmonary carcinoid, monoclonal antibody, clinical diagnostics,

#3361 FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

Introduction: Well-differentiated neuroendocrine tumors (NETs) are relatively rare, highly vascularized neoplasms. Antiangiogenic drugs have shown efficacy in patients with advanced NETs. Bevacizumab is a well-known antiangiogenic monoclonal antibody.

Conference:

Presenting Author:

Authors: Lacombe C, Perrier M, Hentic O, Brixi H, Rebours V,

Keywords: neuroendocrine tumor, antiangiogenic therapy, VEGF, well-differentiated,

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2821 Nucleophosmin Expression and Relocation in Pancreatic Neuroendocrine Tumors: Preliminary Data

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms with unpredictable clinical course and biological behavior. Nucleophosmin (NPM) is an important multifunctional protein mainly located in the nucleolus. NPM has been reported to be overexpressed in many types of human cancer, activating tumor development and progression. However, the role of NPM in PanNETs is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Delektorskaya V, Bukaeva I, Ponomareva M, Smirnova E,

Keywords: neuroendocrine tumor, pancreas, nucleophosmin, immunohistochemistry, prognosis,

#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,

Keywords: PDR001, immunotherapy, NET,